drugset
drugset / Trial / NCT05153148

A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis

NCT05153148 ↗

Phase 2 Completed 305 enrolled Takeda Nimbus Lakshmi, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with active Psoriatic Arthritis (PsA).

Timeline

Start
2022-01-06
Primary completion
2023-05-04
Completion
2023-06-02

Outcome

Met primary endpoint

registry analysis (superiority test); Placebo vs NDI-034858 Medium Dose; p =0.002; Risk Difference (RD) 24.1 (95% CI 8.6 to 39.6); NCT05153148 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Zasocitinib Small molecule — Oral

Indications

psoriatic arthritis